project id: TCGA-BLCA; case submitter id: TCGA-CU-A3QU; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 3.3; rna integrity number: 9.1; age at index: 58; days to birth: -21233; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1953; age at diagnosis: 21233; ajcc pathologic m: M0; ajcc pathologic n: N1; ajcc pathologic stage: Stage IV; ajcc pathologic t: T2b; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 158.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 0.821917808219178; pack years smoked: 15.0; is ffpe: false; composition: Not Reported; initial weight: 940.0; oct embedded: false; preservation method: Unknown; sample id: 75448068-ded8-42f0-bb99-6d1c4b3ffa4e; sample submitter id: TCGA-CU-A3QU-01A; portion id: e221790e-e489-4022-a32c-7d86c0b48ca9; portion submitter id: TCGA-CU-A3QU-01A-11; slide id: f19736eb-e66c-41ac-84fa-6c548c1112d3; slide submitter id: TCGA-CU-A3QU-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 3.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 1.0; percent tumor cells: 96.0; percent tumor nuclei: 99.0; section location: TOP;